A Future-proof HTA System in Europe?

Update: 2021-04-21

Description

SOUNDS OF SCIENCE - EPISODE 1

While the European Commission proposal for a HTA Regulation set the basis for a streamlined and harmonised approach towards HTA, the recent Council compromise text somehow dashed hopes of many HTA experts. How is it different from the initial EC proposal and why it is a matter of concern? How will it impact the small and medium-size companies and the patients they serve?

Where do we go now? What do we want? How can we ensure the HTA system is future-proof, adapted to the next technologies (OMP, ATMPs, Digital Health, etc…)?

A transparent and dynamic Q&A with high-level experts Ana Palma, SOBI and Alexander Natz, EUCOPE.

www.eucope.org

Comments

In Channel

The Revision of the General Pharmaceutical Legislation: European Parliament Reports

2024-05-0643:21

Real-World Evidence (RWE): The need for a multi-stakeholder approach

2023-08-1851:03

Rare Reflections: Impact of the OMP revision on rare disease companies in Europe

2023-07-1140:19

MDR/IVDR: Recent changes and their implications for EU medical device companies

2023-04-1034:27

Trans-Atlantic Innovation : Building bridges between the EU and US life sciences industry

2023-03-1344:27

Rare Disease Day 2023: Improving equitable access and diagnosis for people living with a rare disease

2023-02-2247:51

The new EU HTA Procedure: Getting it right to improve patients' access to innovative therapies

2023-01-3020:28

2022 Year in Review: Perspectives & Resolutions from the EUCOPE Policy Team

2022-12-2131:29

Launch Conditionality: The Impact on Small and Mid-Sized Companies

2022-12-1637:59

Advanced Therapy Medicinal Products (ATMPs): How they will be affected by the General Pharmaceutical Legislation

2022-10-1338:37

Ensuring a robust European Health Data Space (EHDS): Working to create a fit-for-purpose regulatory framework

2022-09-1923:14

Unmet Medical Needs (UMN): Towards a new understanding with a focus on underserved areas

2022-07-1834:22

Overcoming Barriers: Improving Access for Rare Disease Patients through Cross-Border Healthcare

2022-06-0629:44

Increasing Access to Genomic Testing in Europe: The role of national genomics initiatives in increasing uptake of Advanced Diagnostics

2022-05-1025:31

What's next for EU Rare Disease Legislation? Its potential implications for patients and pharma entrepreneurs

2022-02-2122:36

The European Pharmaceutical Strategy: A patient-centred and future-proof framework?